Abstract：
BACKGROUND: Electrophysiologic measures provide an opportunity to inform mechanistic models and possibly biomarker prediction of response. Serotonergic psychedelics (SPs) (i.e., psilocybin, lysergic acid diethylamide (LSD)) and ketamine represent new investigational and established treatments in mood disorders respectively. There is a need to better characterize the mechanism of action of these agents.
METHODS: We conducted a systematic review investigating the spectral signatures of psilocybin, LSD, and ketamine in persons with major depressive disorder (MDD), treatment-resistant depression (TRD), and healthy controls.
RESULTS: Ketamine and SPs are associated with increased theta power in persons with depression. Ketamine and SPs are also associated with decreased spectral power in the alpha, beta and delta bands in healthy controls and persons with depression. When administered with SPs, theta power was increased in persons with MDD when administered with SPs. Ketamine is associated with increased gamma band power in both healthy controls and persons with MDD.
CONCLUSIONS: The studies included in our review were heterogeneous in their patient population, exposure, dosing of treatment and devices used to evaluate EEG and MEG signatures. Our results were extracted entirely from persons who were either healthy volunteers or persons with MDD or TRD.
CONCLUSIONS: Extant literature evaluating EEG and MEG spectral signatures indicate that ketamine and SPs have reproducible effects in keeping with disease models of network connectivity. Future research vistas should evaluate whether observed spectral signatures can guide further discovery of therapeutics within the psychedelic and dissociative classes of agents, and its prediction capability in persons treated for depression.
METHODS: We conducted a systematic review investigating the spectral signatures of psilocybin, LSD, and ketamine in persons with major depressive disorder (MDD), treatment-resistant depression (TRD), and healthy controls.
RESULTS: Ketamine and SPs are associated with increased theta power in persons with depression. Ketamine and SPs are also associated with decreased spectral power in the alpha, beta and delta bands in healthy controls and persons with depression. When administered with SPs, theta power was increased in persons with MDD when administered with SPs. Ketamine is associated with increased gamma band power in both healthy controls and persons with MDD.
CONCLUSIONS: The studies included in our review were heterogeneous in their patient population, exposure, dosing of treatment and devices used to evaluate EEG and MEG signatures. Our results were extracted entirely from persons who were either healthy volunteers or persons with MDD or TRD.
CONCLUSIONS: Extant literature evaluating EEG and MEG spectral signatures indicate that ketamine and SPs have reproducible effects in keeping with disease models of network connectivity. Future research vistas should evaluate whether observed spectral signatures can guide further discovery of therapeutics within the psychedelic and dissociative classes of agents, and its prediction capability in persons treated for depression.
摘要：
背景：电生理措施提供了一个机会来告知响应的机械模型和可能的生物标志物预测。血清素能迷幻药(SP)(即，psilocybin,麦角酰二乙胺（LSD））和氯胺酮分别代表了情绪障碍的新研究和既定治疗方法。需要更好地表征这些试剂的作用机制。
方法：我们进行了系统综述，调查了psilocybin的光谱特征，LSD,重度抑郁症（MDD）患者的氯胺酮，难治性抑郁症（TRD），和健康的控制。
结果：氯胺酮和SPs与抑郁症患者的θ功率增加有关。氯胺酮和SP也与α的光谱功率降低有关，健康对照和抑郁症患者的β和δ带。当与SP一起施用时，当给予SPs时，MDD患者的θ功率增加。氯胺酮与健康对照和MDD患者的伽马带功率增加有关。
结论：我们的综述中包含的研究在其患者群体中是异质的，暴露,用于评估EEG和MEG特征的治疗和设备的剂量。我们的结果完全来自健康志愿者或患有MDD或TRD的人。
结论：评估EEG和MEG光谱特征的现有文献表明，氯胺酮和SP在保持网络连接的疾病模型方面具有可重复的效果。未来的研究前景应该评估观察到的光谱特征是否可以指导进一步发现迷幻剂和解离剂类别中的治疗剂，及其对抑郁症患者的预测能力。
方法：我们进行了系统综述，调查了psilocybin的光谱特征，LSD,重度抑郁症（MDD）患者的氯胺酮，难治性抑郁症（TRD），和健康的控制。
结果：氯胺酮和SPs与抑郁症患者的θ功率增加有关。氯胺酮和SP也与α的光谱功率降低有关，健康对照和抑郁症患者的β和δ带。当与SP一起施用时，当给予SPs时，MDD患者的θ功率增加。氯胺酮与健康对照和MDD患者的伽马带功率增加有关。
结论：我们的综述中包含的研究在其患者群体中是异质的，暴露,用于评估EEG和MEG特征的治疗和设备的剂量。我们的结果完全来自健康志愿者或患有MDD或TRD的人。
结论：评估EEG和MEG光谱特征的现有文献表明，氯胺酮和SP在保持网络连接的疾病模型方面具有可重复的效果。未来的研究前景应该评估观察到的光谱特征是否可以指导进一步发现迷幻剂和解离剂类别中的治疗剂，及其对抑郁症患者的预测能力。
